ScreenerHero
XERSXeris Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · xerispharma.com
8.610USD-1.94%Mkt Cap: 1.60B $P/E: —

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-u…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.60B $
Enterprise Value1.74B $
Revenue (TTM)335.41M $
Gross Profit249.28M $
Net Income (TTM)554.00K $
Revenue/Share1.993 USD
Last Price8.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees435
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS98422E1038
Valuation
P/E (Trailing)—
P/E (Forward)22.05
PEG—
EV/EBITDA35.59
EV/Revenue5.17
P/S4.67
P/B104.88
EPS (TTM)-0.10
EPS (Forward)0.39
52W Range
5.25070% of range10.08
52W High10.08 USD
52W Low5.250 USD
Profitability
Gross Margin85.41%
Oper. Margin5.62%
EBITDA Margin14.54%
Profit Margin0.19%
ROE4.05%
ROA0.14%
Growth
Revenue Growth28.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF28.63M $
CapEx (TTM)696.00K $
FCF Margin15.64%
FCF Yield3.28%
Net Debt167.69M $
Net Debt/EBITDA3.44
Balance Sheet
Debt/Equity18.85
Current Ratio1.45
Quick Ratio0.95
Book Value/Sh0.0820 USD
Cash/Share0.6680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.71 USD
Upside (mean)+36.1%
Target Range8.000 USD – 18.00 USD
$8.000+36.1% to mean$18.00
# Analysts7
Ownership
Shares Out.182.32M
Float175.99M
Insiders3.12%
Institutions59.95%
Short Interest
Short Ratio5.0d
Short % Float5.22%
Short % Out.5.06%
Shares Short9.22M
Short (prev mo.)12.76M
Technical
SMA 508.045 (+7.0%)
SMA 2007.018 (+22.7%)
Beta0.85
S&P 52W Chg18.16%
Avg Vol (30d)1.65M
Avg Vol (10d)1.83M
Technical Indicators
RSI (14)60.6
MACD0.1511
MACD Signal0.1208
MACD Hist.+0.0303
BB Upper8.858 USD
BB Middle8.263 USD
BB Lower7.668 USD
BB Width14.39%
ATR (14)0.3851 USD
Vol Ratio (20d)0.95x